CL Stock Analysis: Colgate-Palmolive | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 74.352m USD | 12M Return: 13.1% | US1941621039 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 421M
EPS Trend: 93.9%
Qual. Beats: 14
Rev. Trend: 91.3%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Colgate-Palmolive Company (NYSE: CL) is a global consumer staples manufacturer headquartered in New York, founded in 1806. It operates through two business segments: Oral, Personal and Home Care (offering products such as toothpaste, hand soaps, shampoos, deodorants, household cleaners, and fabric conditioners under brands including Colgate, Palmolive, Irish Spring, Softsoap, and Fabuloso), and Pet Nutrition (offering Hills Science Diet and Hills Prescription Diet pet foods, plus the Prime100 fresh pet food brand in Australia). Products are distributed through traditional retailers, eCommerce channels, wholesalers, distributors, dentists, veterinarians, and skin health professionals across the U.S. and international markets. As a large-cap household products company, Colgate benefits from steady demand for everyday personal care and cleaning essentials, while its Pet Nutrition segment provides exposure to the growing premium and therapeutic pet food categories, which typically command higher margins than mass-market staples.
- Pet Nutrition margin expansion on Hills Science Diet demand
- FX headwinds pressure emerging market oral care sales
- Commodity costs ease, supporting gross margin recovery
| Net Income: 2.04b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.23 > 0.02 and ΔFCF/TA 3.69 > 1.0 |
| NWC/Revenue: 0.76% < 20% (prev -3.90%; Δ 4.66% < -1%) |
| CFO/TA 0.27 > 3% & CFO 4.46b > Net Income 2.04b |
| Net Debt (7.05b) to EBITDA (4.99b): 1.41 < 3 |
| Current Ratio: 1.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (805.8m) vs 12m ago -1.31% < -2% |
| Gross Margin: 60.42% > 18% (prev 60.57%; Δ -0.15% > 0.5%) |
| Asset Turnover: 122.9% > 50% (prev 114.5%; Δ 8.39% > 0%) |
| Interest Coverage Ratio: 17.04 > 6 (EBIT TTM 4.35b / Interest Expense TTM 255.0m) |
| A: 0.01 (Total Current Assets 6.31b - Total Current Liabilities 6.15b) / Total Assets 16.8b |
| B: 1.61 (Retained Earnings 27.1b / Total Assets 16.8b) |
| C: 0.25 (EBIT TTM 4.35b / Avg Total Assets 17.1b) |
| D: 0.01 (Book Value of Equity 236.0m / Total Liabilities 16.2b) |
| Altman-Z'' = 7.04 = AAA |
| DSRI: 1.05 (Receivables 1.96b/1.77b, Revenue 21.0b/20.0b) |
| GMI: 1.00 (GM 60.57% / 60.42%) |
| AQI: 0.88 (AQ_t 0.35 / AQ_t-1 0.40) |
| SGI: 1.05 (Revenue 21.0b / 20.0b) |
| TATA: -0.14 (NI 2.04b - CFO 4.46b) / TA 16.8b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of August 11, 2026, the stock is trading at USD 93.15 with a total of 2,697,609 shares traded. Over the past week, the price has changed by +3.64%, over one month by +1.57%, over three months by +8.01% and over the past year by +13.06%.
Current recommended Stop Loss: 87.40 (which is 6.2% or 2.3 ATR below the current price).
Colgate-Palmolive has received a consensus analysts rating of 3.77. Therefore, it is recommended to hold CL.
- StrongBuy: 7
- Buy: 6
- Hold: 7
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 99 | 6.2% |
P/E Trailing = 36.5765
P/E Forward = 23.6407
P/S = 3.5327
P/B = 309.5648
P/EG = 2.3189
Revenue TTM = 21.0b USD
EBIT TTM = 4.35b USD
EBITDA TTM = 4.99b USD
Long Term Debt = 7.82b USD (from longTermDebt, last quarter)
Short Term Debt = 34.0m USD (from shortTermDebt, last quarter)
Debt = 8.42b USD (from shortLongTermDebtTotal, last quarter) + Leases 566.0m
Net Debt = 7.05b USD (calculated: Debt 8.42b - CCE 1.37b)
Enterprise Value = 81.4b USD (74.4b + Debt 8.42b - CCE 1.37b)
Interest Coverage Ratio = 17.04 (Ebit TTM 4.35b / Interest Expense TTM 255.0m)
EV/FCF = 21.10x (Enterprise Value 81.4b / FCF TTM 3.86b)
FCF Yield = 4.74% (FCF TTM 3.86b / Enterprise Value 81.4b)
FCF Margin = 18.33% (FCF TTM 3.86b / Revenue TTM 21.0b)
Net Margin = 9.68% (Net Income TTM 2.04b / Revenue TTM 21.0b)
Gross Margin = 60.42% ((Revenue TTM 21.0b - Cost of Revenue TTM 8.33b) / Revenue TTM)
Gross Margin QoQ = 61.48% (prev 60.59%)
Tobins Q-Ratio = 4.85 (Enterprise Value 81.4b / Total Assets 16.8b)
Interest Expense / Debt = 3.03% (Interest Expense 255.0m / Debt 8.42b)
Taxrate = 26.52% (780.0m / 2.94b)
NOPAT = 3.19b (EBIT 4.35b * (1 - 26.52%))
Current Ratio = 1.03 (Total Current Assets 6.31b / Total Current Liabilities 6.15b)
Debt / Equity = 35.69 (Debt 8.42b / totalStockholderEquity, last quarter 236.0m)
Debt / EBITDA = 1.41 (Net Debt 7.05b / EBITDA 4.99b)
Debt / FCF = 1.83 (Net Debt 7.05b / FCF TTM 3.86b)
Total Stockholder Equity = 496.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.89% (Net Income 2.04b / Total Assets 16.8b)
RoE = 410.7% (Net Income TTM 2.04b / Total Stockholder Equity 496.0m)
RoCE = 52.24% (EBIT 4.35b / Capital Employed (Equity 496.0m + L.T.Debt 7.82b))
RoIC = 33.18% (NOPAT 3.19b / Invested Capital 9.62b)
WACC = 4.80% (E(74.4b)/V(82.8b) * Re(5.09%) + D(8.42b)/V(82.8b) * Rd(3.03%) * (1-Tc(0.27)))
Discount Rate = 5.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.32 | Cagr: -1.09%
[DCF] Terminal Value 77.89% ; FCFF base≈3.66b ; Y1≈4.18b ; Y5≈6.08b
[DCF] Fair Price = 106.1 (EV 91.6b - Net Debt 7.05b = Equity 84.6b / Shares 797.2m; r=8.35% [WACC [floored]]; 5y FCF grow 14.48% → 2.50% )
EPS Correlation: 93.92 | EPS CAGR: 6.49% | SUE: 3.86 | # QB: 14
Revenue Correlation: 91.33 | Revenue CAGR: 2.65% | SUE: 0.07 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.93 | Chg30d=+0.80% | Revisions=+0% | Analysts=17
EPS current Year (2026-12-31): EPS=3.87 | Chg30d=+1.61% | Revisions=+10% | GrowthEPS=+5.0% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=4.10 | Chg30d=+1.41% | Revisions=+25% | GrowthEPS=+5.8% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: +17% (up=12, down=8)